Drug Trial News

RSS

Rhythm starts RM-493 clinical trials in obesity patients with genetic deficiency

Rhythm announced today the initiation of the first of a series of clinical trials with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity in individuals with a genetic deficiency in the MC4R pathway.

24 Sep 2013

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim and Eli Lilly and Company today announced results from two post-hoc, pooled analyses of data from placebo-controlled clinical trials, which examined the safety of the dipeptidyl peptidase-4 inhibitor linagliptin in adults with type 2 diabetes.

24 Sep 2013

Alefacept drug shows encouraging results in phase 2 trial for type 1 diabetes

A drug formerly used to treat the skin disorder psoriasis has shown encouraging results in a phase 2 trial to assess its effectiveness in treating type 1 diabetes, according to new research published in The Lancet Diabetes & Endocrinology.

24 Sep 2013

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent.

21 Sep 2013

Applied Integrin Sciences' drug candidate eliminates ovarian cancer tumors in pre-clinical study

Applied Integrin Sciences, Inc. announced today that its first cancer therapeutic drug candidate eliminated all intraperitoneal ovarian cancer tumors in a pre-clinical study testing a novel treatment regimen.

21 Sep 2013

Equatorial Guinea presents design for malaria vaccine trial

Equatorial Guinea's Ministry of Health and Social Security recently presented a design for a malaria vaccine trial as part of the government's efforts to improve the country's public health.

21 Sep 2013

Isis Pharmaceuticals announces preliminary data from ISIS-SMNRx Phase 1 study in infants with SMA

Isis Pharmaceuticals, Inc. announced today that follow-up preliminary data from a single dose, open-label Phase 1 study of ISIS-SMNRx in children with spinal muscular atrophy, show that most SMA children receiving the two highest doses of the drug (6 mg and 9 mg) continued to show improvements in muscle function tests up to 14 months after a single injection of the drug.

19 Sep 2013

Omeros announces initiation of enrollment in OMS824 Phase 2 trial for schizophrenia

Omeros Corporation today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 inhibitor. The trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and a battery of cognitive tests in patients with stable schizophrenia.

19 Sep 2013

First clinical trials to diagnose and treat Alzheimer’s disease

More than a century ago, Alois Alzheimer, a Bavarian physician, first identified the neurodegenerative brain condition that came to be known as Alzheimer's disease. Finding ways to diagnose and treat this disease has frustrated scientists and clinicians ever since.

19 Sep 2013

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Results of a Pfizer-commissioned study published this month in Annals of Internal Medicine reveal that smokers with a past or present diagnosis of major depressive disorder (MDD)* taking varenicline had a significantly higher likelihood of quitting smoking (after 12 weeks and at 52 weeks) than those who were given a placebo.

18 Sep 2013

Creabilis treats first atopic dermatitis patients in CT327 Phase 2b study

Creabilis, a late clinical stage European dermatology company with a focus on pruritus (itch), today announces it has treated the first patients in its Phase 2b study of its lead product, CT327, in patients with atopic dermatitis.

18 Sep 2013

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

GW Pharmaceuticals plc announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.

18 Sep 2013

Intra-articular hyaluronic acid injections safe, effective for patients with knee osteoarthritis

A new meta-analysis of 29 randomized studies involving more than 4,500 patients with knee osteoarthritis found that intra-articular hyaluronic acid injections provided significant improvement in pain and function compared to saline injections.

18 Sep 2013

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

UCF College of Medicine professor Dr. Saleh Naser soon will participate in a clinical trial to test whether a new antibiotic therapy acquired by RedHill Biopharma can be used to treat Crohn's disease patients.

18 Sep 2013

Regado Biosciences announces enrollment of first patient in REGULATE-PCI clinical trial

Regado Biosciences, Inc., a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications, today announced the enrollment of the first patient in its REGULATE-PCI clinical trial.

17 Sep 2013

Acacia Pharma initiates two pivotal Phase 3 studies of APD421 in prevention of PONV

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of two pivotal Phase 3 studies of APD421 in the prevention of post-operative nausea & vomiting (PONV).

17 Sep 2013

arGEN-X announces CTA filing of Phase Ib cancer study with ARGX-111

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody product to enter the clinic this year.

17 Sep 2013

Varenicline drug helps people with depression quit smoking, say researchers

About half of smokers seeking treatment for smoking cessation have a history of depression. Compared with smokers who are not depressed, those who suffer from a major depressive disorder have greater difficulty quitting.

17 Sep 2013

Flecainide, encainide drugs increase risk of sudden cardiac death

Scientists have discovered that a drug which increases the risk of sudden cardiac death interacts with mistranslated protein-coding genes present in heart muscle.

17 Sep 2013

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Affimed Therapeutics AG and The Leukemia & Lymphoma Society today announced a partnership to co-fund a phase 2 trial with the Recruit-TandAb AFM13, a novel tetravalent bispecific antibody directed against human CD30 and CD16A in Hodgkin Lymphoma patients for whom currently available treatments have failed.

16 Sep 2013

Drug Trial News

Rhythm starts RM-493 clinical trials in obesity patients with genetic deficiency

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Alefacept drug shows encouraging results in phase 2 trial for type 1 diabetes

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Applied Integrin Sciences' drug candidate eliminates ovarian cancer tumors in pre-clinical study

Equatorial Guinea presents design for malaria vaccine trial

Isis Pharmaceuticals announces preliminary data from ISIS-SMNRx Phase 1 study in infants with SMA

Omeros announces initiation of enrollment in OMS824 Phase 2 trial for schizophrenia

First clinical trials to diagnose and treat Alzheimer’s disease

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Creabilis treats first atopic dermatitis patients in CT327 Phase 2b study

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

Intra-articular hyaluronic acid injections safe, effective for patients with knee osteoarthritis

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

Regado Biosciences announces enrollment of first patient in REGULATE-PCI clinical trial

Acacia Pharma initiates two pivotal Phase 3 studies of APD421 in prevention of PONV

arGEN-X announces CTA filing of Phase Ib cancer study with ARGX-111

Varenicline drug helps people with depression quit smoking, say researchers

Flecainide, encainide drugs increase risk of sudden cardiac death

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Latest News